Molecular Profiles, a Nottingham, UK-based subsidiary of Columbia Laboratories, has invested in GMP hot melt extrusion (HME) technology as well as further milling equipment, enabling the company to accelerate its formulation development service.
Dr Rob Harris, Chief Technical Officer at Molecular Profiles, said: 'Over the years, our company has gained a strong reputation in advanced characterisation, formulation development and dealing with complex molecules. We have been working in this space for nearly a decade, bringing a high level of understanding to, for instance, the stability and failings that occur in HME.
'Expanding our in-house equipment is all about complementing this expertise by bringing on-stream an even more diverse range of enabling technologies to assist clients in developing challenging compounds.'
He added: 'Supported by our suite of processing and characterisation tools, our new Enabling Technologies Division forms the backbone of our early formulation development services. Using a science-led approach, this team is primarily focused on screening formulation options for challenging molecules, quickly developing effective formulations, and finding solutions to our clients’ product development requirements.'
This is the latest significant venture for Molecular Profiles, which opened its clinical production site last July following a successful inspection by the UK's Medicines and Healthcare products Regulatory Agency (MHRA).
Dovetailing with its development capabilities, the company manufactures a range of dosage forms for clinical trials spanning solids, liquids, semi-solids and inhaled products, including potent compounds.